Moderna's Cancer Bet Takes Center Stage as Index Inclusion Looms
Published on 10/07/2026 at 19:21 | Editorial boerse-global.de
Moderna's stock has become a study in conflicting narratives. On one side sits a pipeline that increasingly points toward oncology; on the other, a valuation that some of Wall Street's most respected analysts consider badly overstretched. The tension between those two views has rarely been sharper than it is right now.
A Market Still Trading on Reflex
Old habits die hard on the trading floor. When unconfirmed reports of a suspected plague outbreak in Russia circulated earlier this week, vaccine makers rallied almost automatically. The World Health Organization quickly classified the general health risk as low, and Citigroup analysts noted that contacts had tested negative. The gains evaporated just as fast as they had appeared.
That such vague headlines can still move Moderna's shares at all says something about how part of the market continues to view the company — through the lens of a pandemic-era crisis profiteer. But anyone who reduces the story to those fleeting episodes misses the far more consequential shift the US group has been engineering for some time.
Merck, Tempus and the Oncology Pivot
The real transformation is unfolding away from viral headlines, in cancer medicine. Moderna announced today that it is widening its collaboration with Merck and Tempus toward the possible commercialization of the cancer vaccine intismeran in combination with Keytruda. The program targets patients with fully resected stage IIB to IV melanoma as well as additional tumor types. Tempus will handle sample logistics and, subject to regulatory approvals, genomic profiling.
Behind the announcement sit concrete clinical results that say far more about the company's future potential than speculation about infection waves. In the Phase 3 INTerpath-001 trial, which enrolled 1,137 patients, the combination delivered positive interim results for recurrence-free and distant metastasis-free survival. Longer-term Phase 2b data spanning five years reinforce the picture: the risk of tumor recurrence or death fell by 49 percent versus Keytruda alone, while the risk of distant metastasis or death dropped by 59 percent. For Moderna, the stakes are about proving that messenger RNA technology can address chronic and life-threatening widespread diseases.
Should investors sell immediately? Or is it worth buying Moderna?
The company is also broadening its industrial and operational base. A newly agreed five-year research alliance with Australian organization CSIRO to investigate vaccines against the Hendra virus is another example of efforts to cement its profile over the long term.
Leadership Reshuffle and a Friday Milestone
On the personnel front, Juan Andres stepped into the newly created role of Chief Operating Officer on October 5, tasked with steering the operational expansion into oncology. Jerh Collins, previously Chief Technical Operations and Quality Officer, is retiring.
Meanwhile, a scheduled index change is drawing close attention. Before trading begins on Friday, October 9, Moderna will join the Nasdaq-100, replacing Warner Bros. Discovery. The move, which had fueled strong inflows in the run-up, is now giving way to consolidation.
The Valuation Gap Widens
The stock is generating an explosive mix of euphoria and skepticism. Today it trades at EUR 164.40, a daily loss of 1.2 percent, as market participants take profits after a months-long climb. Since the start of the year, the gain still adds up to a remarkable 546 percent. The 52-week high stands at EUR 188.64.
Against those advance laurels stand substantial concerns from institutional observers. Citigroup downgraded the stock from Neutral to Sell on September 30, with analyst Geoff Meacham raising the price target from USD 60 to USD 80 while citing an stretched valuation following the rally. Redburn also issued a sell recommendation with a target of USD 81. Meacham explicitly pointed to risks from patent disputes, which represent persistent uncertainty for the business model. Citigroup further warned that the positive trial data had run too far ahead of near-term commercial prospects.
The gap between the current market valuation and the sober models of some experts could hardly be wider. Moderna's future does not hinge on short-lived infection fears but on hard clinical validation in oncology. Whether that hope justifies the astronomical rally is a question the coming trial data and quarterly reports will have to answer. The next concrete catalyst arrives on October 9, when the formal Nasdaq-100 inclusion tests whether demand from passive funds is enough to absorb selling from earlier winners.
Ad
Moderna Stock: New Analysis - 7 October
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
